EntryPoint Capital’s Ironwood Pharmaceuticals IRWD Stock Holding History
Bought
Maintained
Sold
Other funds holding IRWD
AC
SCM
EntryPoint Capital's IRWD Position: Q2 2026 in Review
EntryPoint Capital sold out of Ironwood Pharmaceuticals (IRWD) in Q2 2026, closing a stake of 86,874 shares — an estimated $305K sold.
EntryPoint Capital first reported a position in IRWD in Q4 2023 and held it in 8 quarters. The position peaked at $317K in Q1 2025. 212 funds tracked by Wall St. Rank hold IRWD as of Q2 2026.
- EntryPoint Capital reported no remaining Ironwood Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- EntryPoint Capital sold 86,874 Ironwood Pharmaceuticals shares in Q2 2026, an estimated $305K.
- EntryPoint Capital first reported a position in Ironwood Pharmaceuticals in Q4 2023 and held it in 8 quarters.
- EntryPoint Capital's Ironwood Pharmaceuticals position peaked at $317K in Q1 2025.
- 212 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.